Empowering Travellers: Rapid Nutrition to Launch Azurene Immunity Booster in Q4
London, United Kingdom – 2 October 2023 - Rapid Nutrition PLC (Euronext Growth: ALRPD), the globally renowned health and wellness company, is excited to announce that it is right on track for the highly-anticipated launch of Azurene Immunity Booster in the fourth quarter of this year. As the world prepares for the upcoming winter season, which can be especially challenging for travellers, or those who work in confined spaces.
Azurene Immunity Boost Traveller features a patented blend of herbs drawn from Western, Ayurvedic, and Chinese herbal traditions, known for their effectiveness in alleviating symptoms of sore throats, colds, and flu. What sets this formula apart is the addition of Ashwagandha and Andrographis, meticulously chosen for their immune-boosting properties, tailored to the unique needs of travellers.
This innovative formula is designed to reduce the severity and duration of symptoms associated with mild upper respiratory infections, such as common colds and the flu. Ashwagandha, a time-honored remedy in Ayurvedic medicine, not only supports recovery but also aids the body in managing stress, a common companion to travel-induced challenges.
"Travelling can put considerable stress on our immune systems, leaving us vulnerable to health challenges. Azurene Immunity Boost Traveller is designed for those on the move. It combines the wisdom of multiple herbal traditions with years of intense research based on scholarly literature to assist immune support, and eventual launch of the product worldwide" said Rapid Nutrition CEO Simon St Ledger.
To further enhance its commitment to safety and efficacy, Rapid Nutrition is proud to announce the formulas validation by securing an Australian Listing Number from the Australian Therapeutics Goods Administration (TGA) for Azurene Immunity Booster Traveller.
As the launch date approaches, Rapid Nutrition is dedicated to making Azurene Immunity Boost Traveller readily accessible to travellers worldwide. Information regarding its availability and distribution channels will be shared in due course.
About Rapid Nutrition
Rapid Nutrition is a leading health and wellness company committed to providing innovative solutions for a healthier world. With a focus on research-backed formulas, we empower individuals to optimise their well-being and face life's challenges with confidence.
For more information, please visit http://rnplc.com
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).